UICC_Partnership_Solid_Icon-white-blue_200px.png
Partners
Partnership is at the heart of our strategy, with our members, governments, companies and individuals.

Partnering to drive success for cancer control

Fostering inclusive partnerships represents the foundation of how UICC operates and delivers impact. This is why we work hand in hand with a variety of stakeholders to drive transformational changes and make progress in the fight against cancer. 

Our portfolio of partnerships includes cancer organisations, foundations, and private sector companies with which we have developed long-term commitments based on shared ambitions. 

Together we aim to make a significant difference on the ground through our global leadership in three priority areas: convening, capacity building and advocacy.

UICC Framework
Become a partner

Invest in our priority areas and help us drive change globally. We value our partnerships and strive to build mutually beneficial relationships.

Our partners

Our partners' expertise and engagement are fundamental to drive long-term and measurable changes in cancer control.

Testimonials

Read on to find out how UICC and its partners are working together and connecting for global impact.

 

Give us
your support
UICC_Partnership_Outlined_Icon_Orange.png

58

Partners

active in
UICC_Global_Outlined_Icon_Orange.png

172

Countries

Latest partners news & blog articles
Hong Gwan Seo, CEO, National Cancer Center Korea (NCCK)
18 June 2021
News

NCCK: 20 years of advancing cancer care in the Republic of Korea

On 18th June, the National Cancer Center of Korea (NCCK) marks 20 years of commitment to cancer control in the Republic of Korea and to international collaboration. Interview with Dr Hong Gwan Seo, President of NCCK. 

Woman doctor reading a book in a library, illustrating the publication of the 7th edition of the TNM Atlas based on the UICC TNM Classification of Malignant Tumours
9 June 2021
News

The 7th edition of the UICC TNM Atlas – a pictorial guide to the TNM staging system

The 7th edition of the UICC TNM Atlas has just been published, presenting an illustrated version of the TNM Classification of Malignant Tumours and promoting the uniform application of the TNM classification in cancer practice.

Pile of cut tobacco with cigarettes on dollar bills.
28 May 2021
News

More funding needed for tobacco control to reduce cancer incidence

Tobacco use is the leading preventable cause of cancer today. While the regulatory tools exist to reduce it consumption, there are significant financial hurdles to overcome to see effective measures implemented.

Image shows surgeon at work, emphasising the importance of comprehensive healthcare on in cancer control
25 May 2021
News

How integrated comprehensive cancer care can help drive UHC

UICC members in Indonesia and Thailand talk about how cancer control and care is integrated in their national healthcare systems.

Cigarette end burning with ash forming a dollar sign, emphasising the huge profits generated by the tobacco industry and the heavy influence they use to undermine policy changes and more effective tobacco regulation
21 May 2021
News

Aligning efforts for effective tobacco control

Tobacco control is essential to reducing cancer incidence. The first UICC Virtual Dialogue on the topic held on 12th May provided valuable insight into how to unite the efforts of the cancer and tobacco control communities to implement effective regulation.

Person holding a blister pack of medicine
17 May 2021
News

Cancer treatment threatened by increasingly ineffective antimicrobial drugs

As pathogens become ever more resistant to antimicrobial drugs such as antibiotics, people living with cancer run a growing risk of adverse treatment outcomes, including death from an infection, even though their cancer is treatable.

Our Partners
ASCP_Spelled Out_Flat_2C.jpg
American Society for Clinical Pathology (ASCP)

The American Society for Clinical Pathology (ASCP) is the world’s largest professional membership organisation for pathologists and laboratory professionals. In addition to their educational and certification missions around the world, they maintain a very active global health delivery program focused on laboratory strengthening in all aspects. Through their 10 year + work with PEPFAR, they have improved HIV-related testing and access in ~20 countries, trained more than 3000 individuals, and continue to deliver innovated diagnostics their partners. The Cancer Diagnostics and Treatment in Africa Initiative, created and led by ASCP, aims for 100% access to diagnostics for patients with cancer through on-site assessment, implementation planning, and, ultimately, connectivity to experts around the world through telepathology. With more than 100,000 members, the society’s influence has guided the application and evolution of the pathology and laboratory medicine specialty since 1922. ASCP is leading the way in global health pathology.

Amgen logo
Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Astellas
Astellas

The Astellas Group aims to become a R&D-driven global pharmaceutical company contributing to people’s health. Astellas’s business philosophy has three elements — raison d'être, mission and beliefs. This business philosophy expresses the company’s aim to contribute to the health of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while continuously increasing the Company's enterprise value.

bd_color_rgb_2_25.jpg
Beckton, Dickinson and Company

Beckton, Dickinson and Company (BD) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

Bristol-Myers Squibb Logo
Bristol-Myers Squibb (BMS)

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

Cancerfonden logo
Cancerfonden

Founded in 1951 to support cancer research, the Swedish Cancer Society is an independent non-profit organization with the vision of finding cures for cancer. The overall aim of the Society is to achieve a higher survival rate and a reduction in the incidence of cancer. Their main task is to raise and distribute money for cancer research. As one of the largest financiers of cancer research in Sweden, the Swedish Cancer Society essentially acts as a national research council. Thanks to the organization’s extensive knowledge about cancer, the Swedish Cancer Society is also active in areas such as public opinion and spreading knowledge about cancer, as well as results of cancer research.

CACA logo.jpg
China Anti-Cancer Association (CACA)

Established in 1984, the China Anti-Cancer Association (CACA) is a non-government and non-profit organisation with a mission to unite people involved in all branches of oncology with a shared interest in fighting cancer. CACA is dedicated to improving cancer control in China through increasing the survival rates, and decreasing the incidence and mortality rates of cancer. CACA plays an important role in promoting academic exchange, organising public education, establishing collaboration with international cancer societies, and providing data and advice to the Chinese government for making strategies and policies on cancer control. The branches consist of 45 professional societies, 47 full membership organisations, and 30 local anti-cancer associations with a total membership exceeding 47,000.

CUBEBIO_logo.png
CUBEBIO

CUBEBIO is a biomedical company, headquartered in Seoul, South Korea, dedicated to researching and developing cancer diagnostic biomarkers and in vitro diagnostics. The company also possesses more than 30 patents in relation to cancer diagnosis. Since its establishment, CUBEBIO commits itself to the continuous research and development for global health improvements by detecting cancer early through self-diagnosis by means of urine as a specimen. CUBEBIO’s urine-based self-diagnostic technology enables anyone to check their cancer status fast, accurately, economically, and frequently, thereby making early screening possible and, in the case of cancer patients, allowing them to monitor their cancer for progression or recurrence.

CUBEBIO aims to enter world markets by fostering close working relations with cancer societies, foundations, and research centers in each and every country. By doing so, CUBEBIO works towards creating a new culture where complex cancer diagnostic procedure becomes simpler and more accessible by self-diagnosis, regardless of time and place, and thus emerges as a new global leader in the healthcare industry.

DKG
DKG Krebsgesellschaft

The German Cancer Society (DKG) is the largest scientific and specialist oncology company in Germany with headquarters in Berlin. They are engaged in cancer care on the basis of evidence-based medicine, interdisciplinary and consequent quality standards. In total, DKG has about 7600 members, organised in 24 working groups, 16 regional cancer societies and 34 sponsors from research-based pharmaceutical industries, scientific publishers and health insurances. Since cancers need to be cross-treated and researched, their members are not only medical doctors of all sections, but also basic researchers, medical technical assistants, nurses, psychologists and other professionals who work on cancer.

DKG specialises in certification of oncological care institutions, development of clinical practice guidelines, coordination of guidelines in the framework of the German Guideline Program of Oncology (GGPO), development and transfer of oncological knowledge, and improvement of information given to patients.

Fondation Philantropia
Fondation Philantropia

An umbrella foundation associated with the bank Lombard Odier and a registered charity, Fondation Philanthropia has been helping its donors bring their philanthropic initiatives to fruition in all areas of social responsibility since 2008. It provides philanthropic expertise and support to those who wish to develop a philanthropic project in line with their background, desires and ambitions. The Foundation offers its donors a legal, financial and philanthropic framework for made-to-measure projects.

The Foundation now operates more than 20 personal funds and has received over 115 million Swiss francs in donations, of which over a third has already been distributed or committed. Its donors have been highly committed to the fight against cancer, with over 15 million spent on the cause.

Friends of Cancer Patients (FOCP)
Friends of Cancer Patients (FOCP)

Friends of Cancer Patients UAE (FoCP UAE) charity is a non-profit organisation, founded in September 1999 under the directives and patronage of Her Highness Sheikha Jawaher Bint Mohammed Al Qasimi, Wife of the Ruler of Sharjah, United Arab Emirates (UAE).

FoCP UAE provides a broad spectrum of support for its patients including financial support, which entails covering treatment expenses for chemotherapy, radiation and other needed medications, in addition to expenses for investigative and surgical procedures including bone marrow transplants and prosthetic limbs. FoCP UAE provides transportation and food allowance for underprivileged cancer patients and facilitates sending patients abroad for specialised treatment. FoCP UAE also provides moral support, offering cancer patients and their families psychological consultations and Hajj and Umrah services.

ICONGROUP__CMYK_Logo.png
ICON Group

Icon Group is a leading provider of cancer care across Australasia. Icon believes in bringing the best cancer treatment possible, to as many people as possible, as close to home as possible. They do this through leveraging the latest technology, collaborating with like-minded partners and investing in outstanding people.

Institut National du Cancer
Institut National du Cancer

The French National Cancer Institute (INCa) is the preeminent health and science agency in charge of cancer control in France, created under the Public Health Act of 9th August 2004. It reports to the ministries for Health and for Research.

The Institute is a public interest grouping (GIP) which brings together State representatives, charities, health insurance funds, research organisations and hospital federations. These stakeholders share a common goal of reducing the incidence of avoidable cancers and the number of cancer deaths, improving the quality of life of people with cancer during and after their illness, and reducing inequalities related to cancer.

The Institute provides an integrated approach encompassing all cancer-control dimensions (health, scientific, social and economic) and areas of intervention (prevention, screening, care and research) for the benefit of patients and their relatives.

To catalyse progress, the INCa acts as an interface with patients, their friends and families, the healthcare system users, general public, healthcare professionals, researchers, experts and decision-makers.

MSD be well
MSD (Merck & Co)

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bring forward medicines and vaccines for the world’s most challenging diseases.  MSD is a trade name of Merck & Co., Inc., Kenilworth, N.J., USA. Through their prescription medicines, vaccines, biologic therapies, and animal health products, they work with customers and operate in more than 140 countries to deliver innovative health solutions. MSD also demonstrates their commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.

National Cancer Institute (NCI)
National Cancer Institute (NCI)

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Novartis logo
Novartis Oncology

Novartis Oncology is a global leader in transforming outcomes for people with cancer. We offer a wide range of innovative therapies to help meet patient needs and have one of the strongest, most productive pipelines in the industry. Our research is driven by a distinctive scientific and clinical strategy focused on precision oncology – understanding how cancer develops on a genomic level and developing drugs that hone in on those targets.

Pfizer logo
Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.

Roche logo
Roche

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide.

Sanofi
Sanofi

Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.

UICC Japan
UICC Japan

The Japan National Committee for UICC is a group of Japanese organisations that are members of the Union for International Cancer Control (UICC), gathered to support the UICC to strive to realise the World Cancer Declaration. Currently UICC-Japan is composed of 29 full Japanese UICC members, including major cancer specialists in Japan, cancer centres, research institutes, research funds, hospitals and cancer associations.

Partner testimonials
CUBEBIO

“Through our partnership with UICC, we plan to become a company that supports the global fight against cancer and that promotes the importance of early detection around the globe”

 

Mrs Choi, Eun-Jong, Chief Executive Officer
SPARC project-Uganda

“We are proud that our partnership with UICC on the SPARC mBC Challenge continues to make a positive impact on the lives of women with metastatic breast cancer around the world. We are committed to working with the global breast cancer community to help deliver high-quality and far-reaching care to patients in need.”

Andy Schmeltz, President and General Manager
Explore the topic
Our partners
Partners news and blog articles
Partner testimonials
Become a partner
Last update: 
Wednesday 30 September 2020
Share